Director/PDMR Shareholding

RNS Number : 3464D

Oxford Biomedica PLC

22 March 2011

 



OXFORD BIOMEDICA - DIRECTOR'S INTEREST IN SHARES

Oxford, UK - 22 March 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, has been notified that Dr Alan Kingsman, Chairman of the Company, has transferred part of his interest in Oxford BioMedica plc 1p ordinary shares, comprising 10,293,451 shares, into a designated nominee account.  There is no change to his overall interest in shares, which remains at 15,032,590 shares representing 1.59% of the current issued share capital of the Company.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer	Tel: [phone]
Media Enquiries: Emma Thompson/Amber Bielecka/Katja Toon M:Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

RDSBRGDXSBDBGBB